Rosiglitazone Evaluated for Cardiovascular Outcomes -- An Interim Analysis.


Home, PD; Pocock, SJ; Beck-Nielsen, H; Gomis, R; Hanefeld, M; Jones, NP; Komajda, M; McMurray, JJ; RECORD Study Group, ; (2007) Rosiglitazone Evaluated for Cardiovascular Outcomes -- An Interim Analysis. The New England journal of medicine, 357 (1). pp. 28-38. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa073394

[img]
Preview
Text - Published Version
License: Copyright the publishers

Download (672kB) | Preview

Abstract

: A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes.<br/> : We conducted an unplanned interim analysis of a randomized, multicenter, open-label, noninferiority trial involving 4447 patients with type 2 diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea, in which 2220 patients were assigned to receive add-on rosiglitazone (rosiglitazone group), and 2227 to receive a combination of metformin plus sulfonylurea (control group). The primary end point was hospitalization or death from cardiovascular causes.<br/> : Because the mean follow-up was only 3.75 years, our interim analysis had limited statistical power to detect treatment differences. A total of 217 patients in the rosiglitazone group and 202 patients in the control group had the adjudicated primary end point (hazard ratio, 1.08; 95% confidence interval [CI], 0.89 to 1.31). After the inclusion of end points pending adjudication, the hazard ratio was 1.11 (95% CI, 0.93 to 1.32). There were no statistically significant differences between the rosiglitazone group and the control group regarding myocardial infarction and death from cardiovascular causes or any cause. There were more patients with heart failure in the rosiglitazone group than in the control group (hazard ratio, 2.15; 95% CI, 1.30 to 3.57).<br/> : Our interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes. There was no evidence of any increase in death from either cardiovascular causes or all causes. Rosiglitazone was associated with an increased risk of heart failure. The data were insufficient to determine whether the drug was associated with an increase in the risk of myocardial infarction. (ClinicalTrials.gov number, NCT00379769 [ClinicalTrials.gov].).<br/>

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
PubMed ID: 17551159
Web of Science ID: 247720800006
URI: http://researchonline.lshtm.ac.uk/id/eprint/9850

Statistics


Download activity - last 12 months
Downloads since deposit
550Downloads
275Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item